Folgen
George Papatheodoridis
George Papatheodoridis
Bestätigte E-Mail-Adresse bei med.uoa.gr
Titel
Zitiert von
Zitiert von
Jahr
EASL clinical practice guidelines: management of chronic hepatitis B virus infection
G Papatheodoridis, M Buti, M Cornberg, HLA Janssen, D Mutimer, S Pol, ...
Journal of hepatology 57 (1), 167-185, 2012
5204*2012
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
P Lampertico, K Agarwal, T Berg, M Buti, HLA Janssen, ...
Journal of hepatology 67 (2), 370-398, 2017
45792017
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The Lancet Gastroenterology & Hepatology 2 (3), 161-176, 2017
20612017
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ...
The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018
14642018
2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B
YF Liaw, E Gane, N Leung, S Zeuzem, Y Wang, CL Lai, EJ Heathcote, ...
Gastroenterology 136 (2), 486-495, 2009
9262009
Systematic review: the model for end‐stage liver disease–should it replace Child‐Pugh's classification for assessing prognosis in cirrhosis?
E Cholongitas, GV Papatheodoridis, M Vangeli, N Terreni, D Patch, ...
Alimentary pharmacology & therapeutics 22 (11‐12), 1079-1089, 2005
5702005
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B
SJ Hadziyannis, GV Papatheodoridis, E Dimou, A Laras, C Papaioannou
Hepatology 32 (4), 847-851, 2000
5472000
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy: a systematic review
GV Papatheodoridis, P Lampertico, S Manolakopoulos, A Lok
Journal of hepatology 53 (2), 348-356, 2010
5372010
Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy
GV Papatheodoridis, HLY Chan, BE Hansen, HLA Janssen, P Lampertico
Journal of hepatology 62 (4), 956-967, 2015
5132015
Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment
E Gane, E Lawitz, D Pugatch, G Papatheodoridis, N Bräu, A Brown, S Pol, ...
New England Journal of Medicine 377 (15), 1448-1455, 2017
490*2017
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ...
Journal of Hepatology 64 (4), 800-806, 2016
4552016
Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a metaanalysis
GV Papatheodoridis, J Goulis, G Leandro, D Patch, AK Burroughs
Hepatology 30, 612-22, 1999
4371999
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
YF Liaw, IS Sheen, CM Lee, US Akarca, GV Papatheodoridis, ...
Hepatology 53 (1), 62-72, 2011
4132011
The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B
GV Papatheodoridis, E Manesis, SJ Hadziyannis
Journal of hepatology 34 (2), 306-313, 2001
4092001
Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B
P Marcellin, SH Ahn, X Ma, FA Caruntu, WY Tak, M Elkashab, WL Chuang, ...
Gastroenterology 150 (1), 134-144. e10, 2016
3802016
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment
SJ Hadziyannis, GV Papatheodoridis
Semin Liver Dis 26 (2), 130-141, 2006
3702006
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference
A Hatzakis, S Wait, J Bruix, M Buti, M Carballo, M Cavaleri, M Colombo, ...
Journal of viral hepatitis 18, 1-16, 2011
3492011
Liver grafts from anti-hepatitis B core positive donors: a systematic review
E Cholongitas, GV Papatheodoridis, AK Burroughs
Journal of hepatology 52 (2), 272-279, 2010
3372010
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ...
Hepatology 66 (5), 1444-1453, 2017
3092017
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ...
The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017
3032017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20